share_log

Redhill Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Redhill Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Redhill Biopharma | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  08/13 20:37
牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd. has announced its upcoming Annual General Meeting (AGM) to be held on September 17, 2024. The notice includes several key proposals for shareholder voting, including the reappointment of Kesselman & Kesselman as the company's auditors for 2024, the reelection of Eric Swenden and Ofer Tsimchi, and the election of Dr. Roni Mamluk to the Board of Directors for a three-year term. Additionally, the AGM will address the approval of restricted share units (RSUs) grants to non-executive directors, the company's CEO Dror Ben-Asher, and Chief Commercial Officer Rick D. Scruggs. Shareholders will also have the opportunity to review the company's financial statements for the fiscal year ended December 31, 2023. The meeting will take place at the company's offices in Tel Aviv, Israel, and shareholders of record as of August 6, 2024, are entitled to vote. The Board of Directors recommends voting in favor of all the proposals.
RedHill Biopharma Ltd. has announced its upcoming Annual General Meeting (AGM) to be held on September 17, 2024. The notice includes several key proposals for shareholder voting, including the reappointment of Kesselman & Kesselman as the company's auditors for 2024, the reelection of Eric Swenden and Ofer Tsimchi, and the election of Dr. Roni Mamluk to the Board of Directors for a three-year term. Additionally, the AGM will address the approval of restricted share units (RSUs) grants to non-executive directors, the company's CEO Dror Ben-Asher, and Chief Commercial Officer Rick D. Scruggs. Shareholders will also have the opportunity to review the company's financial statements for the fiscal year ended December 31, 2023. The meeting will take place at the company's offices in Tel Aviv, Israel, and shareholders of record as of August 6, 2024, are entitled to vote. The Board of Directors recommends voting in favor of all the proposals.
RedHill Biopharma Ltd.宣佈其即將於2024年9月17日舉行年度股東大會。通知中包括數項關鍵提案供股東投票，包括重新任命Kesselman＆Kesselman爲公司2024年的核數師，重新選舉Eric Swenden和Ofer Tsimchi，以及選舉Roni Mamluk博士爲董事會成員，任期爲三年。此外，股東大會還將審議向非執行董事、公司CEO Dror Ben-Asher和首席商務官Rick D. Scruggs授予限制性股票單位(RSUs)的批准。股東們還有機會查閱公司截至2023年12月31日的基本報表。該會議將在以色列特拉維夫的公司辦公室舉行。截至2024年8月6日的股東享有投票權。董事會建議投票支持所有提案。
RedHill Biopharma Ltd.宣佈其即將於2024年9月17日舉行年度股東大會。通知中包括數項關鍵提案供股東投票，包括重新任命Kesselman＆Kesselman爲公司2024年的核數師，重新選舉Eric Swenden和Ofer Tsimchi，以及選舉Roni Mamluk博士爲董事會成員，任期爲三年。此外，股東大會還將審議向非執行董事、公司CEO Dror Ben-Asher和首席商務官Rick D. Scruggs授予限制性股票單位(RSUs)的批准。股東們還有機會查閱公司截至2023年12月31日的基本報表。該會議將在以色列特拉維夫的公司辦公室舉行。截至2024年8月6日的股東享有投票權。董事會建議投票支持所有提案。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。